Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.
Tom Zioncheck, head of neuroscience, ophthalmology and rare diseases partnering for Roche and Genentech Inc., told Scrip that 2019 was a “remarkable” year for the company’s pharma partnering group, because the team negotiated 80 significant transactions. That number includes several deals in neuroscience – a therapeutic area where the Swiss big pharma hopes to create a presence similar to its dominant position in oncology.
[Sidebar#SC141498]
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
